Literature DB >> 21884552

Donor heparinization is not a contraindication to liver transplantation even in recipients with acute heparin-induced thrombocytopenia type II: a case report and review of the literature.

R Bachmann1, S Nadalin, J Li, J Lange, R Ladurner, A Königsrainer, A Heininger.   

Abstract

Heparin-induced thrombocytopenia (HIT) type II is caused by an immune-mediated side effect of heparin anticoagulation resulting in a clotting disorder. In the setting of urgent liver transplantation, the question arises whether a graft from a heparinized donor can be safely transplantated in a recipient with even acute heparin-induced thrombocytopenia type II. We report on a patient with end-stage liver disease and acute HIT II waiting for liver transplantation. Despite the risk of life-threatening complications, an organ procured from a heparinized donor was accepted. Assuming heparin residuals within the graft, the donor organ was flushed backtable with increased amounts of Wisconsin solution. The subsequent transplantation and the postoperative course were uneventful; neither thromboses nor graft dysfunction occurred. Even in acute episode of HIT II with circulating antibodies, a patient may receive an organ from a heparin-treated donor, if adequate precautions during organ preparation are observed.
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884552     DOI: 10.1111/j.1432-2277.2011.01323.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  4 in total

Review 1.  Heparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledge.

Authors:  Volker Assfalg; Norbert Hüser
Journal:  World J Transplant       Date:  2016-03-24

2.  Successful liver transplantation in a patient with splanchnic vein thrombosis and pulmonary embolism due to polycythemia vera with Jak2v617f mutation and heparin-induced thrombocytopenia.

Authors:  Emanuela Biagioni; Paola Pedrazzi; Marco Marietta; Fabrizio Di Benedetto; Erica Villa; Mario Luppi; Massimo Girardis
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

3.  Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation.

Authors:  Burcin Ekser; Chih C Lin; Cassandra Long; Gabriel J Echeverri; Hidetaka Hara; Mohamed Ezzelarab; Vladimir Y Bogdanov; Donna B Stolz; Keiichi Enjyoji; Simon C Robson; David Ayares; Anthony Dorling; David K C Cooper; Bruno Gridelli
Journal:  Transpl Int       Date:  2012-05-30       Impact factor: 3.782

4.  Use of Argatroban in Donor Lung Procurement: A Case Report.

Authors:  Limi Sharif; M Andrew Millis; Caitlin T Demarest; Ashraf Abou El Ela; Katie A McMurry; Dennis Lyu; Elliot Wakeam
Journal:  Am J Case Rep       Date:  2021-11-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.